Construction of a <sup>89</sup> Zr-Labeled Specific Antibody Fragment for the Noninvasive Detection of Mesothelin-Overexpressing Tumors
Zr-MA4 is 0.142 mSv/MBq, which complies with established safety standards. Overall, both probes exhibit robust in vitro stability and demonstrate feasibility for MSLN-targeted imaging in vivo.
Authors
- Futao Liu (ORCID: https://orcid.org/0000-0003-4904-8411)
- Lulin Yang
- Zi Wang (ORCID: https://orcid.org/0000-0002-3953-0493)
- Y Yao
- Feng Wang
- Song Liu
- Xingguo Hou
- Changsong Qi
- Zhi Yang (ORCID: https://orcid.org/0000-0003-2084-5193)
- Hua Zhu (ORCID: https://orcid.org/0000-0002-4198-5809)
Institutions
- Xiamen University (CN)
- Peking University (CN)
- National Medical Products Administration (CN)
- Peking University Cancer Hospital (CN)
- Peking University Shenzhen Hospital (CN)
- Ministry of Education (ET)
- Institute of Biomedical Science (GB)
- Indiana University School of Medicine
Publication Details
- Journal
- Molecular Pharmaceutics
- Published
- 2026-05-12
- DOI
- https://doi.org/10.1021/acs.molpharmaceut.6c00244
- Primary Topic
- Occupational and environmental lung diseases
- Type
- article
- Field-Weighted Citation Impact
- 0.00